Table 2 Chemotherapy regimens of the MDR-TB patients
Variable | Chemotherapy regimen | N (%) |
|---|---|---|
Individualized regimen | Distinct from patient-to-patient | 63 (45.3%) |
Regimen 1 | 6 Pyrazinamide Amikacin Levofloxacin Cycloserine Protionamide | 42 (30.2%) |
/18 Pyrazinamide Levofloxacin Cycloserine Protionamide | ||
Regimen 2 | 6 Pyrazinamide Amikacin Levofloxacin Para-amino salicylic acid Protionamide | 16 (11.5%) |
/18 Pyrazinamide Levofloxacin Para-amino salicylic acid Protionamide | ||
Regimen 3 | 6 Pyrazinamide Capreomycin Levofloxacin Cycloserine Protionamide | 3 (2.2%) |
/18 Pyrazinamide Levofloxacin Cycloserine Protionamide | ||
Regimen 4 | 6 Pyrazinamide Capreomycin Levofloxacin Para-amino salicylic acid Protionamide | 15 (10.8%) |
/18 Pyrazinamide Levofloxacin Cycloserine Protionamide |